New therapeutic targets in the treatment of prostate cancer.
Androgen deprivation therapy has become the mainstay of the treatment of advanced prostate cancer, being used in every clinical setting of the disease, from neoadjuvant to metastatic disease. Despite success in controlling the disease in the majority of men, hormonal manipulations will eventually fail. New agents are being developed for patients with hormone refractory disease. Important advances in molecular oncology have improved our understanding regarding the cellular mechanisms that regulate cell death in the prostate. It is hoped that these new insights will lead to development of more efficacious and easy to tolerate therapies for cancer prostate. This review focuses on the current literature on tumor vaccines, angiogenesis inhibitors, antisense oligonucleotides, differentiation agents, cancer-specific genes, endothelial receptor antagonists, anti-apoptotic agents, agents acting on signaling pathways and androgen and estrogen receptors.
Vijjan
Vivek
V
Department of Urology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow - 226 014, India.
Dubey
Deepak
D
Clin Cancer Res. 2001 Jul;7(7):1888-93
11448901
Int J Cancer. 1994 Oct 1;59(1):126-32
7523313
Cancer Res. 2001 May 1;61(9):3689-97
11325840
J Clin Oncol. 2003 Jan 1;21(1):123-8
12506180
J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):309-16
8877724
J Urol. 1999 Jan;161(1):173-5
10037392
Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6
11685731
Urology. 2005 May;65(5 Suppl):9-16; discussion 17
15885273
J Clin Oncol. 2002 Apr 15;20(8):2171-80
11956279
Urology. 1998 Jul;52(1):72-81
9671874
Urology. 2004 Aug;64(2):311-5; discussion 315-6
15302485
Urology. 1999 May;53(5):1063-9
10223507
Clin Cancer Res. 2002 Aug;8(8):2530-5
12171880
Semin Oncol. 2001 Aug;28(4 Suppl 15):67-70
11685732
Clin Cancer Res. 2006 Feb 15;12(4):1260-9
16489082
Prostate. 1999 Apr 1;39(1):54-9
10221267
Clin Cancer Res. 2000 May;6(5):1632-8
10815880
Clin Cancer Res. 2001 May;7(5):1198-203
11350884
J Clin Oncol. 2005 Jan 20;23(3):455-60
15659491
BJU Int. 2006 Apr;97(4):691-7
16536755
J Clin Oncol. 2000 Dec 1;18(23):3894-903
11099318
Physiol Rev. 2001 Jul;81(3):1269-304
11427696
Cancer Chemother Pharmacol. 1997;39(4):349-56
9025776
Clin Cancer Res. 2000 Mar;6(3):838-46
10741705
Cancer Res. 1990 Apr 15;50(8):2311-5
2317818
Cancer Chemother Pharmacol. 1998;41(2):133-9
9443626
Cancer Res. 2000 Feb 15;60(4):829-33
10706088
J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000
12837835
Urology. 2003 Nov;62(5 Suppl 1):34-43
14607216
J Immunol. 1998 Sep 15;161(6):3186-94
9743387
Clin Cancer Res. 2001 Dec;7(12):3920-7
11751483
BJU Int. 2005 Dec;96 Suppl 2:30-4
16359436
Prostate. 1999 Jan 1;38(1):73-8
9973112